MAP · ASX

Microba Life Sciences Limited (ASX:MAP)

AU$0.1

 0.012 (12.903%)
ASX:Live
18/07/2025 02:50:03 PM
Recent Price downgrade HALO Ords HALO Consensus Value GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

MAP Overview

MAP Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About MAP

Website

N/A

Telephone

61.13.0097.4621

Address

Level 10 324 Queen Street Brisbane, Queensland (QLD) 4000

Description

Microba Life Sciences Ltd. engages in the provision of microbiome testing, supplements and analysis services as well as developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. It operates through the Testing Services and Supplements and Research and Development segments. The company was founded by Gene Tyson and Philip Hugenholtz on January 31, 2017 and is headquartered in Brisbane, Australia.

MAP Price Chart

Key Stats

Market Cap

AU$46.87M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.08 - 0.32

Trade Value (12mth)

AU$11,692.00

1 week

-1.06%

1 month

-19.13%

YTD

-52.31%

1 year

-43.64%

All time high

0.42

Key Fundamentals

EPS 3 yr Growth

87.60%

EBITDA Margin

-197.90%

Operating Cashflow

-$16m

Free Cash Flow Return

-38.70%

ROIC

-49.60%

Interest Coverage

-345.60

Quick Ratio

2.40

Other Data

Shares on Issue (Fully Dilluted)

448m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.54

MAP Announcements

Latest Announcements

Date Announcements

17 July 25

Details of Q4 FY25 Quarterly Report, Appendix 4C & Webinar

×

Details of Q4 FY25 Quarterly Report, Appendix 4C & Webinar

08 July 25

Letter to Shareholders, Notice of EGM & Proxy Form

×

Letter to Shareholders, Notice of EGM & Proxy Form

02 July 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

27 June 25

Application for quotation of securities - MAP

×

Application for quotation of securities - MAP

27 June 25

Disclosure Document - Prospectus

×

Disclosure Document - Prospectus

27 June 25

Letter to SPP Eligible Shareholders

×

Letter to SPP Eligible Shareholders

27 June 25

Cleansing Notice

×

Cleansing Notice

23 June 25

Suspension from Quotation

×

Suspension from Quotation

23 June 25

Microba secures $14.5 million to drive clinical adoption

×

Microba secures $14.5 million to drive clinical adoption

23 June 25

Proposed issue of securities - MAP

×

Proposed issue of securities - MAP

23 June 25

Strategic Investment & Equity Raise Presentation

×

Strategic Investment & Equity Raise Presentation

23 June 25

Proposed issue of securities - MAP

×

Proposed issue of securities - MAP

23 June 25

Proposed issue of securities - MAP

×

Proposed issue of securities - MAP

23 June 25

Proposed issue of securities - MAP

×

Proposed issue of securities - MAP

23 June 25

Reinstatement to Quotation

×

Reinstatement to Quotation

19 June 25

Trading Halt

×

Trading Halt

21 May 25

MetaPanel Pathogen Study Delivers Breakthrough Results

×

MetaPanel Pathogen Study Delivers Breakthrough Results

14 May 25

Landmark GI Study Results from over 4,600 patients

×

Landmark GI Study Results from over 4,600 patients

12 May 25

Notification of cessation of securities - MAP

×

Notification of cessation of securities - MAP

30 April 25

Q3 FY25 Quarterly Activities Report & Appendix 4C

×

Q3 FY25 Quarterly Activities Report & Appendix 4C

30 April 25

Q3 FY25 Quarterly Investor Presentation & Webinar

×

Q3 FY25 Quarterly Investor Presentation & Webinar

28 April 25

Details of Q3 FY25 Quarterly Report, Appendix 4C & Webinar

×

Details of Q3 FY25 Quarterly Report, Appendix 4C & Webinar

02 April 25

HealthInvest 2025 Investor Conference Presentation

×

HealthInvest 2025 Investor Conference Presentation

20 March 25

Diagnostics Growth & Metrics Webinar - Part B

×

Diagnostics Growth & Metrics Webinar - Part B

20 March 25

Webinar Presentation - Diagnostics Deep Dive - Part A

×

Webinar Presentation - Diagnostics Deep Dive - Part A

MAP Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.04 -0.05 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.04 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.5 3.5 -27.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -73.0 15.8 -25.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -22.0 -13.7 -26.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.12 0.11 0.09 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.11 0.10 0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 135.7 -12.8 -55.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 291 333 410 Lock Lock Lock
Basic m Lock Lock Lock Lock 291 333 410 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 5 5 12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 25.6 15.6 123.1 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 9 13 18 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -8 -7 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.1 12.6 -26.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -165.3 -125.0 -71.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 265 225 171 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -15 -19 -24 Lock Lock Lock
     Growth % Lock Lock Lock Lock -76.3 -26.2 -28.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -314.1 -342.9 -197.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 3 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -16 -20 -27 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.0 -24.3 -32.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -347.1 -373.2 -221.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -19 -26 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -6 -6 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -11 -13 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.5 -10.5 -57.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -244.6 -233.9 -164.9 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -10 -12 -16 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 2 3 4 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -2 -3 -14 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 29 17 18 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -12 -13 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.7 -7.1 -31.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2.6 -2.4 -1.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 31 32 21 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 39 47 58 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -29 -31 -19 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 6 8 16 Lock Lock Lock
Equity $m Lock Lock Lock Lock 34 39 41 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 34 39 42 Lock Lock Lock
     Growth % Lock Lock Lock Lock 126.8 14.1 7.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -29.1 -27.0 -34.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.2 -32.9 -48.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -65.0 -54.2 -64.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -46.8 -34.8 -49.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -42.6 -34.0 -38.7 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -266.4 -307.6 -345.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.0 1.7 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -87.8 -80.1 -46.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.8 5.3 2.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 6.7 5.2 2.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.0 77.2 64.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -198.5 -158.4 -125.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 1.8 1.0 1.6 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 28.5 24.3 14.3 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.2 0.2 0.6 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 17.3 55.0 30.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -244.4 -346.3 -213.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -29.0 -40.0 -44.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -29.1 -27.0 -34.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.2 -32.9 -48.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -34.2 -32.9 -48.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 12.8 15.0 25.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 197.4 358.9 231.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 210.3 373.9 257.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 17.3 55.5 54.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 192.9 318.4 202.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

MAP Shortsell

Frequently Asked Questions

The current share price of Microba Life Sciences Limited (MAP:ASX) is AU$0.1.
The 52-week high share price for Microba Life Sciences Limited (MAP:ASX) is AU$0.32.
The 52-week low share price for Microba Life Sciences Limited (MAP:ASX)? is AU$0.08.
Microba Life Sciences Limited (MAP:ASX) does not pay a dividend.
Microba Life Sciences Limited (MAP:ASX) does not pay a dividend.
Microba Life Sciences Limited (MAP:ASX) has a franking level of 0.0%.
Microba Life Sciences Limited (MAP:ASX) is classified in the Healthcare.
The current P/E ratio for Microba Life Sciences Limited (MAP:ASX) is .
The current share price of Microba Life Sciences Limited (MAP:ASX) is AU$0.1.
The 52-week high share price for Microba Life Sciences Limited (MAP:ASX) is AU$0.32.
The 52-week low share price for Microba Life Sciences Limited (MAP:ASX)? is AU$0.08.
Microba Life Sciences Limited (MAP:ASX) does not pay a dividend.
Microba Life Sciences Limited (MAP:ASX) does not pay a dividend.
Microba Life Sciences Limited (MAP:ASX) has a franking level of 0.0%.
Microba Life Sciences Limited (MAP:ASX) is classified in the Healthcare.
The current P/E ratio for Microba Life Sciences Limited (MAP:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.